Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Neglected Disease Consortium Formed

by Lisa M. Jarvis
August 24, 2009 | A version of this story appeared in Volume 87, Issue 34

A team of scientists from industry, academia, and the nonprofit sector are collaborating to find new treatments for African sleeping sickness and leishmaniasis, two neglected tropical diseases that kill a total of 100,000 people each year. The consortium, which is starting out with $5 million to be distributed over the course of four years, includes IOTA Pharmaceuticals, Mercachem, Nycomed, the Drugs for Neglected Diseases Initiative, the Royal Tropical Institute, the University of Bern, VU University Amsterdam, and TI Pharma. The group aims to find and develop new drug candidates that block parasite-specific phosphodiesterase, which plays a role in cell proliferation and death.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.